Ocugen, Inc.

OCGN Healthcare Biotechnology

Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024. In the quarter to June 2026, revenue grew 8.38%, EPS fell 40.0%, free cash flow fell 13.4% and total debt fell 93.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.78 0.03 −3.70%
Market cap
$275.9M
P/E
0.0×
Fwd P/E
−5.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.40
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 2 2 2

+8 more TTM periods

ROE
1,211.66% (660.00%) (776.89%) (289.93%)
ROA
(92.03%) (118.11%) (107.73%) (107.12%)
ROIC
0.00% (1,317.07%) 0.00% 0.00%
Return on Tangible Assets
628.74% (226.29%) (432.44%) (198.67%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.18) (0.18) (0.19) (0.18)
Free Cash Flow
(61.02) (59.58) (57.15) (53.53)
Other line items

Show all line items

Columns are period end dates